STAT+: FDA’s rejection of Moderna threatens to stifle broader vaccine industry 

The FDA has reversed its earlier decision and will now review Moderna's mRNA-based flu vaccine, which it had previously declined. This change has been described as a "surprise rejection" by Ars Technica and has raised concerns among experts regarding the implications for the vaccine industry. The FDA's actions have been characterized as creating a "destructive precedent" that could undermine future vaccine development in the U.S., according to STAT+. Experts have noted that the FDA "moved the goalposts" on Moderna, which may lead to uncertainty for other vaccine developers. Moderna expressed optimism that its new flu shot could be available this year following the FDA's decision to review the vaccine. CBS News reported that the reversal of the FDA's earlier decision is seen as a positive development for drugmakers and vaccine developers, although it also highlights ongoing chaos within the agency. The Washington Post noted that this situation reflects broader issues within the FDA, which has faced criticism for its handling of vaccine approvals. The implications of the FDA's reversal extend beyond Moderna, as it may affect the confidence of other pharmaceutical companies in the regulatory process. The decision to review the flu vaccine is a significant development in the context of ongoing discussions about vaccine innovation and regulatory standards in the U.S. The situation underscores the complexities and challenges faced by the FDA in balancing safety, efficacy, and the need for timely vaccine availability.